The authors reply

New England Journal of Medicine

Volumn 369, Issue 25, 2013, Pages 2457-

  Finkelstein, Joel S ^a   Yu, Elaine W ^a   Burnett Bowie, Sherri Ann M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GONADORELIN AGONIST; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BODY FAT; BONE DENSITY; CARDIOVASCULAR DISEASE; ESTROGEN DEFICIENCY; FAT MASS; GROWTH HORMONE RELEASE; HUMAN; HYPOGONADISM; LETTER; LOW DRUG DOSE; MEDICAL ETHICS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; BODY COMPOSITION; DEFICIENCY; LIBIDO; MALE; MUSCLE STRENGTH; PHYSIOLOGY; NOTE;

BODY COMPOSITION; ESTRADIOL; HUMANS; LIBIDO; MALE; MUSCLE STRENGTH; TESTOSTERONE;

EID: 84890344797     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1313169     Document Type: Letter

References (4)

1. The Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA 1973;226:652-7.
2. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-70.
3. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003;88:204-10.
4. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000;106:1553-60.